Palatin Technologies (PTN)
(Delayed Data from AMEX)
$1.49 USD
+0.01 (0.68%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $1.47 -0.02 (-1.34%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 101 - 120 ( 201 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Laser Focus on BMT While Valeant''s Efforts Remain Limp
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Sprout Investors are Steaming; KOL Views Validated; BMT Sitting Pretty
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
KOL Dinner: As Addyi Falters Early, BMT Set To Deliver the Goods
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
BMT Sets the Mood. Want a Drink? No Problem. Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q16 Results; Swelling Excitement for Phase III Data in 3Q16
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F1Q16 Results; It''s Crunch Time for Management to Deliver
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Focusing on Value Creating Catalysts for Our CoverageThis report contains brief updates on the following: ADRO, AGTC, APHB, APTO, ARGS, BLRX, CFRX, CNCE, CYTK, CYTX, IMNP, PTN, STML, T.TST. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2015 Results; Putin and Richter''s Flaccid Business Provides Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Names for the Turn and the Long Haul
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
BMT Primed, Ready and Sitting Pretty After Valeant/Sprout Deal
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Flibanserin Approved; Market''s Ready Willing and Able for BMT
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J